Shopping Cart 0
Cart Subtotal
AED 0

Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 22020
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline Review, H2 2017, provides an overview of the Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline landscape.

Vasomotor symptoms of menopause include hot flashes or night sweats that result from sudden opening of the blood vessels close to the skin, usually due to hormonal fluctuations in menopause and perimenopause. These symptoms are caused due to some medications, estrogen withdrawal, thyroid disease, diabetes, hyperhidrosis, anxiety and panic disorders, obesity, hormonally active tumors, chronic infections and neurological disorders.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Vasomotor Symptoms of Menopause (Hot Flashes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 3, 2 and 1 respectively.

Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health).

The pipeline guide reviews pipeline therapeutics for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Vasomotor Symptoms of Menopause (Hot Flashes)-Overview

Vasomotor Symptoms of Menopause (Hot Flashes)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Vasomotor Symptoms of Menopause (Hot Flashes)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Vasomotor Symptoms of Menopause (Hot Flashes)-Companies Involved in Therapeutics Development

AstraZeneca Plc

EndoCeutics Inc

MenoGeniX Inc

Mithra Pharmaceuticals SA

N4 Pharma Plc

Ogeda SA

Pherin Pharmaceuticals Inc

TherapeuticsMD Inc

Vasomotor Symptoms of Menopause (Hot Flashes)-Drug Profiles

(estradiol + progesterone)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(estradiol acetate + progesterone)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acolbifene hydrochloride + prasterone-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Estetrol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fezolinetant-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FP-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HBN-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MNGX-100-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NT-814-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

paroxetine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pavinetant-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PH-80HF-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Q-122-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vasomotor Symptoms of Menopause (Hot Flashes)-Dormant Projects

Vasomotor Symptoms of Menopause (Hot Flashes)-Discontinued Products

Vasomotor Symptoms of Menopause (Hot Flashes)-Product Development Milestones

Featured News & Press Releases

Oct 13, 2017: Mithra Announces Completion of Recruitment in Donesta Phase II Study

Oct 05, 2017: TherapeuticsMD Announces Multiple Presentations Related to TX-001HR at NAMS

May 15, 2017: Millendo Therapeutics Announces MLE4901 Data Presentations at European Congress of Endocrinology and Congress of the European Menopause and Andropause Society

Apr 03, 2017: TherapeuticsMD Presents Positive Phase 3 Data in Two Presentations for TX-001HR at ENDO

Jan 04, 2017: Ogeda announces positive data from Phase IIa trial of fezolinetant (ESN364) in the treatment of menopausal hot flashes

Dec 20, 2016: Ogeda announces fezolinetant as INN and issuance of U.S. patent for ESN

Dec 05, 2016: TherapeuticsMD Announces Positive Top-Line Results from Pivotal Phase 3 Replenish Trial in Postmenopausal Women with Moderate to Severe Vasomotor Symptoms (VMS) Treated with TX-001HR

Sep 14, 2016: Euroscreen SA: Completes Enrollment in Phase II trial of lead candidate ESN364 in Menopausal Hot Flashes

Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials

Oct 13, 2015: TherapeuticsMD Completes Enrollment in Phase 3 Clinical Trial of Bio-identical Oral Combination of Estradiol and Progesterone Product Candidate

Sep 23, 2015: Euroscreen launches Phase 2 clinical trial with ESN364 as the first and unique non-hormonal causal treatment for menopausal Hot Flashes

Jan 06, 2014: TherapeuticsMD Announces Milestone Achievement of 50th Site for Phase 3 Clinical Trial of TX 12-001HR to Treat Symptoms of Menopause and Provide Endometrial Protection

Oct 18, 2013: TherapeuticsMD Poster Wins First-Place Prize at the North American Menopause Society 2013 Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline by AstraZeneca Plc, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline by EndoCeutics Inc, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline by MenoGeniX Inc, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline by Mithra Pharmaceuticals SA, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline by N4 Pharma Plc, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline by Ogeda SA, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline by Pherin Pharmaceuticals Inc, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline by TherapeuticsMD Inc, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes)-Dormant Projects, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes)-Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

AstraZeneca Plc

EndoCeutics Inc

MenoGeniX Inc

Mithra Pharmaceuticals SA

N4 Pharma Plc

Ogeda SA

Pherin Pharmaceuticals Inc

TherapeuticsMD Inc

Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline Review, H2 2017, provides an overview of the Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline landscape.

Vasomotor symptoms of menopause include hot flashes or night sweats that result from sudden opening of the blood vessels close to the skin, usually due to hormonal fluctuations in menopause and perimenopause. These symptoms are caused due to some medications, estrogen withdrawal, thyroid disease, diabetes, hyperhidrosis, anxiety and panic disorders, obesity, hormonally active tumors, chronic infections and neurological disorders.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Vasomotor Symptoms of Menopause (Hot Flashes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 3, 2 and 1 respectively.

Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health).

The pipeline guide reviews pipeline therapeutics for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Vasomotor Symptoms of Menopause (Hot Flashes)-Overview

Vasomotor Symptoms of Menopause (Hot Flashes)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Vasomotor Symptoms of Menopause (Hot Flashes)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Vasomotor Symptoms of Menopause (Hot Flashes)-Companies Involved in Therapeutics Development

AstraZeneca Plc

EndoCeutics Inc

MenoGeniX Inc

Mithra Pharmaceuticals SA

N4 Pharma Plc

Ogeda SA

Pherin Pharmaceuticals Inc

TherapeuticsMD Inc

Vasomotor Symptoms of Menopause (Hot Flashes)-Drug Profiles

(estradiol + progesterone)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(estradiol acetate + progesterone)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

acolbifene hydrochloride + prasterone-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Estetrol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fezolinetant-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FP-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HBN-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MNGX-100-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NT-814-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

paroxetine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pavinetant-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PH-80HF-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Q-122-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vasomotor Symptoms of Menopause (Hot Flashes)-Dormant Projects

Vasomotor Symptoms of Menopause (Hot Flashes)-Discontinued Products

Vasomotor Symptoms of Menopause (Hot Flashes)-Product Development Milestones

Featured News & Press Releases

Oct 13, 2017: Mithra Announces Completion of Recruitment in Donesta Phase II Study

Oct 05, 2017: TherapeuticsMD Announces Multiple Presentations Related to TX-001HR at NAMS

May 15, 2017: Millendo Therapeutics Announces MLE4901 Data Presentations at European Congress of Endocrinology and Congress of the European Menopause and Andropause Society

Apr 03, 2017: TherapeuticsMD Presents Positive Phase 3 Data in Two Presentations for TX-001HR at ENDO

Jan 04, 2017: Ogeda announces positive data from Phase IIa trial of fezolinetant (ESN364) in the treatment of menopausal hot flashes

Dec 20, 2016: Ogeda announces fezolinetant as INN and issuance of U.S. patent for ESN

Dec 05, 2016: TherapeuticsMD Announces Positive Top-Line Results from Pivotal Phase 3 Replenish Trial in Postmenopausal Women with Moderate to Severe Vasomotor Symptoms (VMS) Treated with TX-001HR

Sep 14, 2016: Euroscreen SA: Completes Enrollment in Phase II trial of lead candidate ESN364 in Menopausal Hot Flashes

Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials

Oct 13, 2015: TherapeuticsMD Completes Enrollment in Phase 3 Clinical Trial of Bio-identical Oral Combination of Estradiol and Progesterone Product Candidate

Sep 23, 2015: Euroscreen launches Phase 2 clinical trial with ESN364 as the first and unique non-hormonal causal treatment for menopausal Hot Flashes

Jan 06, 2014: TherapeuticsMD Announces Milestone Achievement of 50th Site for Phase 3 Clinical Trial of TX 12-001HR to Treat Symptoms of Menopause and Provide Endometrial Protection

Oct 18, 2013: TherapeuticsMD Poster Wins First-Place Prize at the North American Menopause Society 2013 Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline by AstraZeneca Plc, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline by EndoCeutics Inc, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline by MenoGeniX Inc, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline by Mithra Pharmaceuticals SA, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline by N4 Pharma Plc, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline by Ogeda SA, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline by Pherin Pharmaceuticals Inc, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes)-Pipeline by TherapeuticsMD Inc, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes)-Dormant Projects, H2 2017

Vasomotor Symptoms of Menopause (Hot Flashes)-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

AstraZeneca Plc

EndoCeutics Inc

MenoGeniX Inc

Mithra Pharmaceuticals SA

N4 Pharma Plc

Ogeda SA

Pherin Pharmaceuticals Inc

TherapeuticsMD Inc

chat_bubbleLet's Chat